Økonomiske fordeler

Restrictive blood transfusion practices are associated with improved patient outcomes. (åpner nytt vindu)

Goodnough LT, Maggio P, Hadhazy E, Shieh L, Hernandez-Boussard T, Khari P, Shah N.

Kilde‎: Transfusion 2014;54(10 Pt 2):2753-9.

Arkiv‎: PubMed 24995770

DOI‎: 10.1111/trf.12723

https://www.ncbi.nlm.nih.gov/pubmed/24995770 (åpner nytt vindu)

Improved outcomes and reduced costs associated with a health-system-wide patient blood management program: a retrospective observational study in four major adult tertiary-care hospitals. (åpner nytt vindu)

Leahy MF, Hofmann A, Towler S, Trentino KM, Burrows SA, Swain SG, Hamdorf J, Gallagher T, Koay A, Geelhoed GC, Farmer SL.

Kilde‎: Transfusion 2017;57(6):1347-58.

Arkiv‎: PubMed 28150313

DOI‎: 10.1111/trf.14006

https://www.ncbi.nlm.nih.gov/pubmed/28150313 (åpner nytt vindu)

Cost-effectiveness of recombinant human erythropoietin for reducing red blood cells transfusions in critically ill patients. (åpner nytt vindu)

MacLaren R, Sullivan PW.

Kilde‎: Value Health 2005;8(2):105-16.

Arkiv‎: PubMed 15804319

DOI‎: 10.1111/j.1524-4733.2005.04006.x

https://www.ncbi.nlm.nih.gov/pubmed/15804319 (åpner nytt vindu)

Implementation of a patient blood management monitoring and feedback program significantly reduces transfusions and costs. (åpner nytt vindu)

Mehra T, Seifert B, Bravo-Reiter S, Wanner G, Dutkowski P, Holubec T, Moos RM, Volbracht J, Manz MG, Spahn DR

Kilde‎: Transfusion 2015;55(12):2807-15.

Arkiv‎: PubMed 26264557

DOI‎: 10.1111/trf.13260

https://www.ncbi.nlm.nih.gov/pubmed/26264557 (åpner nytt vindu)

Trauma-induced coagulopathy: impact of the early coagulation support protocol on blood product consumption, mortality and costs. (åpner nytt vindu)

Nardi G, Agostini V, Rondinelli B, Russo E, Bastianini B, Bini G, Bulgarelli S, Cingolani E, Donato A, Gambale G, Ranaldi G

Kilde‎: Crit Care 2015;19:83.

Arkiv‎: PubMed 25880548

DOI‎: 10.1186/s13054-015-0817-9

https://www.ncbi.nlm.nih.gov/pubmed/25880548 (åpner nytt vindu)

The CRASH-2 trial: a randomised controlled trial and economic evaluation of the effects of tranexamic acid on death, vascular occlusive events and transfusion requirement in bleeding trauma patients. (åpner nytt vindu)

Roberts I, Shakur H, Coats T, Hunt B, Balogun E, Barnetson L, Cook L, Kawahara T, Perel P, Prieto-Merino D, Ramos M, Cairns J, Guerriero C.

Kilde‎: Health Technol Assess 2013;17(10):1-79.

Arkiv‎: PubMed 23477634

DOI‎: 10.3310/hta17100

https://www.ncbi.nlm.nih.gov/pubmed/23477634 (åpner nytt vindu)

Reversal of coagulopathy in critically ill patients with traumatic brain injury: recombinant factor VIIa is more cost-effective than plasma. (åpner nytt vindu)

Stein DM, Dutton RP, Kramer ME, Scalea TM.

Kilde‎: J Trauma 2009;66(1):63-72.

Arkiv‎: PubMed 19131807

DOI‎: 10.1097/TA.0b013e318191bc8a

https://www.ncbi.nlm.nih.gov/pubmed/19131807 (åpner nytt vindu)

Effect of a restrictive transfusion strategy on transfusion-attributable severe acute complications and costs in the US ICUs: a model simulation. (åpner nytt vindu)

Zilberberg MD, Shorr AF.

Kilde‎: BMC Health Serv Res 2007;7:138.

Arkiv‎: PubMed 17764560

DOI‎: 10.1186/1472-6963-7-138

https://www.ncbi.nlm.nih.gov/pubmed/17764560 (åpner nytt vindu)

BEHANDLING AV AKUTT KRITISK SYKDOM

Økonomiske fordeler

Norsk

Økonomiske fordeler

https://assetsnffrgf-a.akamaihd.net/assets/ct/e781f8601f/images/syn_placeholder_sqr.png

Restrictive blood transfusion practices are associated with improved patient outcomes. (åpner nytt vindu)

Improved outcomes and reduced costs associated with a health-system-wide patient blood management program: a retrospective observational study in four major adult tertiary-care hospitals. (åpner nytt vindu)

Cost-effectiveness of recombinant human erythropoietin for reducing red blood cells transfusions in critically ill patients. (åpner nytt vindu)

Implementation of a patient blood management monitoring and feedback program significantly reduces transfusions and costs. (åpner nytt vindu)

Trauma-induced coagulopathy: impact of the early coagulation support protocol on blood product consumption, mortality and costs. (åpner nytt vindu)

The CRASH-2 trial: a randomised controlled trial and economic evaluation of the effects of tranexamic acid on death, vascular occlusive events and transfusion requirement in bleeding trauma patients. (åpner nytt vindu)

Reversal of coagulopathy in critically ill patients with traumatic brain injury: recombinant factor VIIa is more cost-effective than plasma. (åpner nytt vindu)

Effect of a restrictive transfusion strategy on transfusion-attributable severe acute complications and costs in the US ICUs: a model simulation. (åpner nytt vindu)

Kontakt lokal representant for sykehuskontaktutvalget

Medisinsk informasjonsmateriale

Videoer

Økonomiske fordeler

Velg ditt språk

Del